Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference



    Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference

PR Newswire

LA JOLLA, Calif., May 21, 2013

LA JOLLA, Calif., May 21, 2013 /PRNewswire/ -- Regulus Therapeutics Inc.
(NASDAQ: RGLS), a biopharmaceutical company leading the discovery and
development of innovative medicines targeting microRNAs, today announced that
Garry E. Menzel, Ph.D., Chief Operating Officer and Executive Vice President,
Finance, will present a company overview at the Deutsche Bank 38th Annual
Healthcare Conference on Wednesday, May 29, 2013 at 3:30 pm EDT.  The
conference is being held at the Westin Boston Waterfront Hotel.

The presentation will be webcast at the time of the presentation and can be
accessed on the Investor Relations page of the Company's website at
www.regulusrx.com.  A replay of each webcast will be archived on the Company's
website following the presentation date.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company
leading the discovery and development of innovative medicines targeting
microRNAs.  Regulus is leveraging a mature therapeutic platform based on
technology that has been developed over 20 years. Regulus works with a broad
network of academic collaborators and leverages the oligonucleotide drug
discovery and development expertise of its founding companies, Alnylam
Pharmaceuticals and Isis Pharmaceuticals.  Regulus is developing RG-101 for
the treatment of HCV and is advancing other microRNA therapeutics toward
clinical development in several areas, including oncology, fibrosis and
metabolic diseases. Regulus has formed strategic alliances with AstraZeneca,
GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
associated with Regulus' expectations regarding future therapeutic and
commercial potential of Regulus' business plans, technologies and intellectual
property related to microRNA therapeutics being discovered and developed by
Regulus.  Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or implied by such
forward-looking statements. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be incorrect.  Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of various risks
and uncertainties, which include, without limitation, risks associated with
the process of discovering, developing and commercializing drugs that are safe
and effective for use as human therapeutics, and in the endeavor of building a
business around such drugs.  These and other risks concerning Regulus'
programs are described in additional detail in Regulus' SEC filings.  All
forward-looking statements contained in this press release speak only as of
the date on which they were made. Regulus undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after
the date on which they were made.

SOURCE Regulus Therapeutics Inc.

Website: http://www.regulusrx.com
Contact: Amy Conrad, Director, Investor Relations and Corporate
Communications, Regulus Therapeutics Inc., 858-202-6300,
aconrad@regulusrx.com; David Schull, Russo Partners LLC, 212-845-4271,
david.schull@russopartnersllc.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement